EMA Investigates Finasteride’s Link to Suicidality – Potential for EU Ban

The European Medicines Agency (EMA) has initiated a detailed review of finasteride, assessing links between its use and suicidality, including suicidal ideation, attempts, and completed suicides. Led by the Pharmacovigilance Risk Assessment Committee (PRAC), this five-month probe will evaluate all available data and could lead to label changes, market suspension, or withdrawal in the EU.

Finasteride, commonly prescribed for hair loss and prostate enlargement, is in fact dangerous, with mounting evidence revealing its capacity to trigger serious, lasting effects on mental health and physical function. Some users report experiencing post-finasteride syndrome (PFS), a debilitating condition that can cause cognitive impairment, severe anxiety, sexual dysfunction, and physical side effects that persist long after discontinuing the drug. The almost always irreversible nature of these symptoms has raised alarm within medical and regulatory communities.

“PFS likely represents types of iatrogenic epigenetic damage previously unseen in human history. On the individual level, the consequences are catastrophic, and there may be population-level effects as well. Increasing our knowledge and understanding of these increasingly prevalent disorders is paramount.”

— Dr. Anthonei Csoka, Biogerontologist and Associate Professor in the Department of Anatomy at Howard University

While the EMA’s investigation into suicidality is a significant and essential step, it is problematic that the scope of this review is so narrowly focused on suicides and suicidal ideation alone. Finasteride’s impact extends far beyond mental health, affecting numerous bodily systems and leading to a range of persistent, often devastating symptoms. The drug’s capacity to disrupt hormonal, neurological, and sexual health is well-documented, and limiting the investigation to suicidality overlooks the broader, deeply concerning picture of harm that finasteride can inflict on the human body. We find it highly concerning that the full extent of finasteride’s damage remains unexamined in this probe, as comprehensive action is crucial to ensure the safety of those affected.

Over 200 companies marketing finasteride and dutasteride in Europe must submit information on suicidality risks by December 2024. Recent warnings by regulatory agencies in the UK, Canada, and Japan have heightened focus on the drug’s psychiatric side effects.

EMA’s recommendations, expected in February 2025, may have significant implications, potentially reducing finasteride’s availability in 30 European nations. This review is a meaningful step forward for PFS patients worldwide. As regulatory bodies acknowledge and investigate the serious risks linked to finasteride, we’re witnessing essential progress for those suffering its effects. By bringing these issues to light, we’re moving closer to a future where PFS patients receive the recognition, support, and safety measures they deserve.

About SIDEfxHUB

SIDEfxHUB is dedicated to raising awareness about post-finasteride syndrome (PFS) and the dangers of 5-alpha reductase (5AR) inhibitors like finasteride. We work tirelessly to educate the public, medical professionals, and policymakers about the severe, often irreversible effects of these drugs, which can include cognitive impairment, severe anxiety, and physical dysfunction. Through our research, advocacy, and patient support initiatives, we aim to shed light on the hidden risks of 5AR inhibitors, advocating for greater recognition, improved patient safety, and vital regulatory changes. Our mission is to ensure that those affected receive the support and awareness they deserve.